Concepedia

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

Michael Friedländer, Val Gebski, Emma Gibbs, Lucy Davies, Ralph Bloomfield, Felix Hilpert, Lari Wenzel, Daniel Eek, Manuel Rodrigues, Andrew R. Clamp,

The Lancet Oncology · 2018 · 137 citations · 18 references

DOIFull text

Open access

Concepts

References

18

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

Jonathan A. Ledermann, Philipp Harter, Charlie Gourley et al. · New England Journal of Medicine · 2012 · 1.9K citations

, , +14

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

, , +14

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

Jonathan A. Ledermann, Philipp Harter, Charlie Gourley et al. · The Lancet Oncology · 2014 · 1.4K citations

, , +16

The PCORI Perspective on Patient-Centered Outcomes Research

Lori Frank, Ethan Basch, Joe V. Selby · JAMA · 2014 · 583 citations

, , +13